In detail, all these results indicate that total Tau in plasma has a higher ability to distinguish AD patients from non-MCI controls (AUC = 0.7993, P < 0.0001), while between aMCI and non-MCI controls, or between AD and aMCI, the performance is moderate (aMCI vs. non-MCI: 0.6909, P = 0.0002; AD vs. aMCI: 0.6698, P = 0.0006) (Figure 4B). The gene discussed is MAPT; the disease is Alzheimer disease.